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RÉSUMÉ
L’influence de la plasmaphérèse sur le niveau d’anti-
corps anti-ovariens chez les femmes stériles pendant 
la phase préparatoire de la fécondation in vitro
Introduction. L’étude d’auto-anticorps anti-ovariens 
(AAO) chez les patients avec insuffisance ovarienne 
dans le contexte des niveaux normaux de gonadotro-
phine, de la prolactine et des androgènes montre que 
l’incidence d’ovarite auto-immunisée parmi de telles 
femmes varie de 19,2% à 31,5%.
Les matériaux et les procédés. Nous avons exa-
miné 30 femmes qui ont été divisées dans les groupes 
suivants: le groupe de contrôle – 10 femmes en bonne 
santé reproductive avec une naissance dans l’histoire 
(de 1 à 3); le groupe principal – 20 femmes avec in-
fertilité d’origine tubaire, qui ont été incluses dans le 
programme de fécondation in vitro.
Résultats. Le niveau d’AAO parmi les femmes in-
fertiles s’est révélé être 1,7 fois moins élevé que dans 
le groupe de contrôle. La réduction du niveau d’anti-
corps anti-ovariens chez les patients du groupe prin-
cipal a été marquée par les antécédents obstétrique et 
gynécologique .
ABSTRACT
Introduction. The study of anti-ovarian autoantibod-
ies in patients with ovarian insufficiency against the 
background of normal levels of gonadotropins, prolac-
tin and androgens shows that the incidence of auto-
immune oophoritis among such women varies from 
19.2% to 31.5%.
The objective of the study was to study the an-
ti-ovarian antibodies level in infertile women at the 
preparatory stage for in vitro fertilization.
Materials and methods. We examined 30 women, 
who were divided into the following groups: control 
group – 10 reproductively healthy women, who had 
a birth in the history (from 1 to 3); study group – 20 
women with infertility of tube origin, who were in-
cluded in the in vitro fertilization program. The study 
was performed between 2015-2017 in the Bukovinian 
State Medical University and Centre of Reproductive 
Medicine, Ukraine. The women signed the informed 
consent.
Results. The anti-ovarian antibodies level in infer-
tile women was found out to be 1.7 times less than in 
the control group. Reduction of the level of anti-ovar-
ian antibodies in patients from the study group was 
marked by the obstetric and gynecological history.
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INTRODUCTION
The autoantibodies do not appear in a normal 
organism, since there is a danger of uncontrolled 
self-destruction of its own tissues, without obvious 
causes, and even its complete death1-3. Therefore, the 
appearance of antibodies against the own antigens is 
blocked4,5. However, in some situations, the autoanti-
bodies may have a physiological role6-8,. The appear-
ance of antibodies against the damaged tissues may 
have (in some degree) a sanogenic role, since it allows 
them to be removed more quickly from the body9-11.
Natural autoantibodies in healthy individuals 
may also be specific autoantibodies in autoimmune 
diseases. According to some authors, such „healthy“ 
individuals, in whom the autoantibodies are detect-
ed, are sooner or later candidates for the appearance 
of the corresponding autoimmune diseases, since the 
latter manifest themselves only after accumulation of 
a certain critical number of antibodies, in accordance 
with the law of the transfer of quantity in quality12-14.
Anti-ovarian antibodies (AOA) damage various 
ovarian structures, including cell surfaces of the skin, 
yellow body, oocytes (eggs) and separate cells in the 
interstitial ovaries. Autoimmune oophoritis with 
lymphocytic infiltrates, cystic and atresia of follicles 
have been described15-18. Anti-ovarian antibodies are 
found in 22.7% of women with primary infertility 
and 37.5% with secondary infertility included in the 
program of extracorporal fertilization19-23.
Some authors pointed to the association of 
anti-ovarian antibodies with endometriosis and 
subsequent failures with implantation of embryos. 
Anti-ovarian antibodies may appear during intracor-
poral fertilization programs, as a result of repeated 
hormonal stimulation and microarray of ovaries 
when extracting oocytes24-28. The study of anti-ovar-
ian autoantibodies in patients with ovarian insuffi-
ciency against the background of normal levels of 
gonadotropins, prolactin and androgens, shows that 
the incidence of autoimmune oophoritis among such 
women varies from 19.2% to 31.5%29-35 .
THE OBJECTIVE OF THE STUDY was the determination 
of anti-ovarian antibodies level in infertile women, at 
the preparatory stage for in vitro fertilization.
MATERIALS AND METHODS
We examined 30 women, who were divided into 
the following groups:
 Control group – 10 reproductively healthy women, 
who had a birth in the history (from 1 to 3).
 Study group – 20 women with infertility of tube 
origin, were included in the in vitro fertilization 
program.
The study was performed in Bukovinian State 
Medical University and Centre of Reproductive 
Medicine, Ukraine, between 2015-2017.
Along with the definition of anti-ovarian anti-
bodies, the determination of hormonal homeosta-
sis, indicators of nonspecific and specific immune 
defense, ultrasound of the pelvic organs, were per-
formed.
The determination of anti-ovarian antibodies 
was carried out using the immunosorbent assay of 
Bioserv Ovari-Antibodi-ELISA for the determination 
of autoantibodies directed against ovarian antigens 
in blood serum. This analysis is based on an indi-
rect solid-phase method. Statistical processing was 
performed using the STATISTICA-5.5 A software 
package (StatSoft, Inc., USA). The reliability of the 
difference (p <0,05) was determined using Student’s 
t-criterion.
RESULTS AND DISCUSSION
The average age of women in the study group 
was not significantly different from the age of the 
control group patients: 30.4±0.4 and 33.6±0.6 years, 
Conclusions. Les anticorps anti-ovariens sont pré-
sents chez les femmes en bonne santé reproductive 
et chez les patientes infertiles. Le niveau d’anticorps 
anti-ovariens peut-être à la fois augmenté et réduit, en 
fonction du processus pathologique, qui a causé l’in-
fertilité. Et dans les deux cas ce fait peut témoigner 
l’infertilité. Après la plasmaphérèse, un taux élevé 
d’anticorps anti-ovariens diminue fortement, indi-
quant son efficacité et la possibilité d’utilisation dans 
le programme pour la préparation in vitro.
Mots-clés: anticorps anti-ovariens, infertilité, fé-
condation in vitro.
Conclusions. Anti-ovarian antibodies are present in 
both reproductively healthy women and in patients 
with infertility. The level of anti-ovarian antibodies 
can be both increased and reduced, depending on the 
pathological process that caused infertility. In both 
cases, this fact can testify the infertility. After plasma-
pheresis, the increased level of anti-ovarian antibodies 
sharply decreases.
Keywords: anti-ovarian antibodies, infertility, in vitro 
impregnation.
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respectively (p> 0,05). In the study group, the number 
of women with menstrual irregularities was signifi-
cantly higher (53.9±3.4% versus 26.9±2.9%).
As shown in Table 1, chronic salpingo-oophoritis 
was diagnosed in 12 women from the study group, 
which corresponds to 60±3.7%, whereas in the con-
trol group only 2 patients had chronic salpingo-oo-
phoritis, corresponding to 20±1.2%. Significant prev-
alence of women with chronic salpingo-oophoritis in 
the study group indicates the possibility of autoim-
mune salpingo-oophoritis in this group of patients.
From the history of the TORCH infection study 
presented in Table 1, in the main group, the Herpes 
simplex virus was observed in 8 patients (40±1.2%). 
Cytomegalovirus was detected in 7 patients in the 
study group (35±0.9%).
7 patients from the study group have been pos-
itive at Chlamydia screening (Table 1) (35±0.9%). As 
shown in the same table, 4 patients from the study 
group have been positive for Ureaplasma, correspond-
ing to 20±0.8%. Mycoplasmosis and Trichomoniasis 
were not detected in the study group. Toxoplasma 
was determined in 10 patients (50±0.9%). Candida 
Fungi were detected in 3 patients from the study 
group (15±2.3%).
Compared to the control group, the herpes 
simplex virus was not detected. Cytomegalovirus 
was detected in one female from the control group 
(10±0.1%), which is significantly lower compared 
with the study group. Toxoplasma was detected in 
one woman from the control group (10±0.1%), 10 
times less than in the main group. Candida Fungi 
were found in one woman (10±0.1%), which is 3 times 
less than in the study group.
The level of anti-ovarian antibodies is shown in 
Table 2.
In the control group, the level of anti-ovarian 
antibodies was 7.1±0.9, and in the study group – 
4.1±0.5, which is 1.7 times less than in the control 
group.
Reduction of the level of anti-ovarian antibodies 
in patients of the study group was marked by the fact 
that the obstetric and gynecological history was bur-
dened in this group and manifested as chronic salpin-
go-oophoritis, artificial abortions, spontaneous abor-
tions, ovarian diseases, including ovarian polycystic 
syndrome, ovarian-menstrual cycle disorders, curet-
tage of the uterus, oral contraceptives, laparoscopic 
surgery, repeated stimulation superovulation, which 
could lead to depletion of the ovaries. Depending on 
Table 1. Indicators of the inflammation in examined women (M ± m)
History Data
Number of Patients
In the study group, n=20 In the control group n=10
abs. % abs. %
Chronic salpingophoritis 12 60±3.7 2 20±1.2
TORCH-infections
Herpes simplex virus 8 40±1.2 – –
Cytomegalovirus 7 35± 0.9 1 10±0.1
Chlamydia 7 35±0.9 – –
Ureaplasma 4 20±0.8 – –
Mycoplasma – – – –
Toxoplasma 10 50±0.9 1 10±0.1
Trichomoniasis – – – –
Candida Fungi 3 15±2.3 1 10±0.1
Table 2. Level indicators of anti-ovarian antibodies in the examined women
Groups of women understudy n= Indices of antibody p
Study group 20 4.1±0.5 <0,05
Control group 10 7.1±0.9 >0,05
Table 3. Indicators of positive and negative results with the IVF of women of the main group
Subgroups of the main 
group
Number of patients 
in the group
Number of pregnancies Number of failures Number of unknown results
abs. % abs. % abs. %
1st subgroup 38 15 39.4 16 42.1 7 18.4
2nd subgroup 20 10 50.0 8 40 2 10.0
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the level of AOA, the functional activity of the ova-
ries can be assessed.
Plasmapheresis was conducted prior to the 
in vitro fertilization program. Before and after the 
plasmapheresis, the level of serum anti-ovarian an-
tibodies in patients with infertility of tubal origin 
was determined. In the group of women undergoing 
plasmapheresis, there were women with positive and 
negative results of IVF (Table 3).
10 women had positive results, representing 
50.0% of all women in the second subgroup. 8 wom-
en (40.0%) from the second subgroup had negative 
results. 10.0% of all patients in the second subgroup 
were women whose results of artificial insemination 
were unknown for one reason or another.
A group of patients who did not undergo plas-
mapheresis consisted of 38 women, who had posi-
tive and negative results of artificial insemination. 
15 women had positive results, representing 39.4% 
of the total number of people in this subgroup. 16 
women had negative results, which is 42.1% of the to-
tal number of people in this subgroup. 7 women had 
unknown results of artificial insemination (18.4%).
The second subgroup of the main group was rep-
resented by women with more burdened obstetric and 
gynecological history. For example, out of four wom-
en with positive results of artificial insemination, two 
went through the program for the first time, and the 
other two – repeatedly, twice and three times.
After analyzing the data presented in Table 4, 
we can see that the first subgroup was made up of 
patients who had been prepared for IVF, and the 
second group consisted of patients who had our pro-
posed preparation for IVF with the inclusion of plas-
mapheresis.
The treatment group consisted of 20 women, 
with a level of anti-ovarian antibodies of 4.1±0.4 IU/
ml. In the process of preparation for the IVF, the 
group was divided into 2 subgroups. In subgroup 1, 
after the traditional preparation for IVF, the level of 
anti-ovarian antibodies was 4.6±0.8 IU/ml, which is 
slightly more than the level of antibodies before the 
preparation. In 2 subgroups, the level of anti-ovarian 
antibodies after our proposed preparation with the in-
clusion of plasmapheresis to IVF was 3.2±0.5 IU/ml, 
which is 1.3 times less than before the preparation.
Consequently, after plasmapheresis, the in-
creased level of anti-ovarian antibodies sharply de-
creases, indicating its effectiveness and the possibility 
of use in the program for IVF preparation.
CONCLUSIONS AND PERSPECTIVES OF FURTHER 
RESEARCH
Anti-ovarian antibodies are present in both re-
productively healthy women and in patients with in-
fertility. The level of anti-ovarian antibodies can be 
both increased and reduced, depending on the patho-
logical process that caused infertility. In both cases, 
this can testify for infertility. After plasmapheresis, 
the increased level of anti-ovarian antibodies sharply 
decreases, indicating its effectiveness and the pos-
sibility of use in the program for IVF preparation. 
The obtained results may be the basis for further 
in-depth, large-scale study of the peculiarities of the 
development of autoimmune salpingo-oophoritis.
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